

**Cocrystal Pharma, Inc.** is a clinical-stage biotechnology company employing its unique structure-based technologies and Nobel Prize-winning expertise to create and develop first- and best-in-class broad-spectrum antiviral drugs for serious and/or chronic diseases. These technologies are designed to efficiently deliver small-molecule therapeutics that target the viral replication process and are safe, effective and convenient to administer. Cocrystal's development programs include influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus.

## Investment Highlights

- **Applying proprietary structure-based drug design technology** to develop broad-spectrum antivirals with high barriers to resistance.
- **Large market opportunities** for the treatment of acute and chronic viral diseases including influenza, COVID-19, hepatitis C and norovirus gastroenteritis.
- **Product candidates** are tested for multiple routes of delivery including oral, inhalation and injection.
- **Robust development pipeline** of antiviral programs including a Merck collaboration for seasonal and pandemic influenza.
- **Seasoned leadership** includes biotech veterans with proven success in drug discovery and development, business and finance, and two Nobel laureates on the Scientific Advisory Board.
- **Cost-efficient business** model with cash runway beyond 2022 and a clean capital structure.

## Technology Overview and Development Pipeline

- **Structure-based drug discovery platform** featuring proprietary structural biology, enzymology and medicinal chemistry expertise.
- **3-D structure of inhibitor complexes** at near-atomic resolution helps to identify novel binding sites and allows for the rapid turnaround of structural information through highly automated x-ray data processing and refinement.
- **Broad-spectrum antiviral activity and high barrier to resistance** for any virus strains by developing drug candidates that specifically target viral replication.
- **Market-driven development** programs aimed at expanding treatment options.

Program		Discovery	Preclinical	Phase 1	Phase 2a	Phase 2b	Phase 3
Influenza A/B	Influenza A/B inhibitor	In collaboration with  <b>MERCK</b>					
Pandemic Influenza A	CC-42344 PB2 Inhibitor	▶					
COVID-19 (Licensed from KSURF)	CDI-45205 Protease Inhibitor	▶					
COVID-19	Replication Inhibitors	▶					
Hepatitis C (HCV)	CC-31244 Pan-genotypic NS5B NNI	▶					
Norovirus (Gastroenteritis)	Replication and Protease Inhibitors	▶					

## Development Programs


### Influenza A/B Collaboration with Merck



- Potent dual influenza candidates expected to be active against seasonal, pandemic and existing drug-resistant influenza strains.

**January 2019:** Announced exclusive worldwide license and collaboration agreement with Cocrystal eligible to receive up to \$156 million in milestone payments plus royalties on future net product sales.

**January 2021:** Announced the completion of all research obligations under the agreement to discover and develop proprietary influenza A/B antiviral agents. Merck has now assumed sole responsibility including funding for continued product development and commercialization activities.



## Pandemic Influenza A Program

**Addressing major U.S. and global concern:** Drug-resistant issues with currently approved therapies

- Exhibits broad-spectrum activity against seasonal and pandemic strains
- Favorable preclinical safety profile and pharmacokinetic properties
- Multiple routes of administration include oral, inhalation and injection

**3Q21:** Initiate Phase 1 Study

## COVID-19 Programs

Targeting viral replication complex with potential *first-in-class therapeutic and prophylactic treatments*.

**2020:** Acquired exclusive patent rights and know-how from Kansas State University Research Foundation (KSURF) for coronavirus and norovirus therapeutics for human use.

**4Q20:** Selected preclinical lead, CDI-45205, to be developed for injectable and inhalation administration.

**2021:** Working toward pre-IND status with CDI-45205.  
Developing additional COVID-19 inhibitors with novel mechanisms of action.

## Hepatitis C Program

CC-31244, a liver-targeting, orally administered, best-in-class non-nucleoside inhibitor (NNI) effective against known NNI drug-resistant variants.

**Favorable Phase 2a study results in combination therapy**

- 6 weeks of Eplclusa therapy including 2 weeks of CC-31244; well tolerated
- 8 of 12 subjects (67%) achieved virologic cure; 4 who did not reach virologic cure had low levels of a biomarker that can be used for patient selection going forward

**Benefits of ultrashort treatment strategy**

- Addresses limitations of existing long-term therapy: longer period for virus to replicate and mutate; increased risk of adverse events; greater opportunity for missed doses
- Proven rapid commercial success with shorter treatment regimens

**Seeking partner for further development**

## Norovirus Program

**Potential for first therapy** with ongoing lead molecule discovery

- Estimated \$60 billion worldwide in annual cost due to direct healthcare expenses and loss of productivity

**1H21:** Complete proof-of-concept animal study

### Investor Contact

LHA Investor Relations  
Jody Cain  
jcain@lhai.com  
310-691-7100

## Management Team

**Gary Wilcox, Ph.D. - Chair and CEO**

35+ years of executive biotech leadership experience; played a key role in the development of Cialis

**Sam Lee, Ph.D. - President**

25+ years of anti-infective drug discovery research experience; played a key role in the early development of phosphoinositide 3-kinase (PI3K) delta inhibitors

**James J. Martin - CFO**

25+ years of finance and management experience including providing financial leadership to commercial-stage, publicly traded health science companies

## Scientific Advisory Board

**Roger Kornberg, Ph.D.**

Director, Chief Scientist, SAB Chair  
Professor, Stanford University  
School of Medicine  
Nobel Laureate

**Michael Levitt, Ph.D.**

Professor, Stanford University  
School of Medicine  
Nobel Laureate

**Baek Kim, Ph.D.**

Director of Center for Drug  
Discovery, Emory University

**Bob Lehman, Ph.D.**

Professor (Emeritus), Stanford  
University School of Medicine

**Gary Schoolnik, M.D.**

Professor (Emeritus), Stanford  
University School of Medicine

**Roland Strong, Ph.D.**

Professor, Fred Hutchinson Cancer  
Research Center

**Christophe Verlinde, Ph.D.**

Professor (Emeritus), University  
of Washington

## Financial Snapshot

- \$33.1 million in cash/ equivalents as of 12/31/20
- No debt, no preferred stock, only 243,000 warrants
- ~\$800,000 cash burn/month in 2021
- Cash runway beyond 2022

The information contained herein was obtained from the management of Cocrystal and other sources LHA believes to be reliable. LHA is engaged by Cocrystal as its investor relations firm. This document contains forward-looking statements, including statements regarding future effectiveness of drug candidates, the achievement of value-driving milestones in each of Cocrystal's programs, and the expected results of collaboration with Merck, including future milestone payments. Investors should consult the "Risk Factors" in the Form 10-K for the year ended December 31, 2020, as updated by subsequent Form 10-Qs. The forward-looking statements in this document speak only as of the date hereof, and there is no intent or obligation to revise or update publicly any forward-looking statement except as required by law. This document shall not constitute an offer to sell, or the solicitation of an offer to buy, securities.

April 2021